Ananda Developments Plc: Medical Cannabis to be Made Available on Prescription Within the UK

LONDON, July 26, 2018 /PRNewswire/ --

Ananda Developments plc (TIDM: ANA) ("Ananda" or the "Company") is pleased with the news from Home Secretary, the Rt Hon Sajid Javid, that cannabis-derived products that meet safety and quality standards will be reclassified by the autumn so that they can be prescribed by specialist clinicians without the need for a special licence within the UK.

Melissa Sturgess, Executive Director of Ananda commented: "We are delighted with this news from the Home Secretary.  Not only will it assist many people, and especially children, who are battling epilepsy and other ailments, it adds very useful legal support to companies like Ananda who wish to invest in the medical cannabis space.

Since listing on the NEX earlier this month, the directors of Ananda have made very good progress in identifying suitable first investments for the Company.  This news supports our efforts."

Ananda was established to invest in the developing market for medicinal or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the USA, as well as other countries around the world, changing their laws to allow for products containing constituents of Medicinal Cannabis to be developed, approved and sold.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

Ananda Developments plc
Melissa Sturgess
Jeremy Sturgess-Smith
+44-(0)739-269-6517

Peterhouse Capital Limited
Fungai Ndoro
Mark Anwyl
+44-(0)20-7469-0930